Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab Plus Apatinib in Advanced Hepatocellular Carcinoma
NCT07192848Phase 2Not yet recruiting
- Start
- Sep 2025
- Primary completion
- Jun 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab in hepatocellular carcinoma (HCC). Planned start Sep 2025; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07192848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07192848.